A novel , fully bacterially produced recombinant virus-like particle ( VLP ) based influenza vaccine ( gH1-Qbeta ) against A/California/07 / 2009 ( H1N1 ) was tested in a double-blind , randomized phase I clinical trial at two clinical sites in Singapore .